CDISC Teams Up with Microsoft to Develop Open-Source Software for the Clinical Research Community

CDISC is teaming up with Microsoft to develop the CDISC Open Rules Engine (CORE), open-source software that executes machine-readable CDISC Conformance Rules. The global clinical research community will be able to leverage the CORE software to test study data for conformance to CDISC standards as well as regulatory and sponsor-specific conformance rule sets.

CDISC Conformance Rules as well as regulatory agency rules provide a critical quality check in ensuring study data conform to CDISC standards. An emerging industry best practice is to use Conformance Rules on an ongoing basis, throughout the study, to keep the data as close to submission ready as possible and to ensure quality in all data exchange scenarios. The free and open, Microsoft Azure-based CORE will execute Conformance Rules retrieved from the CDISC Library against standardized clinical research data and produce a report detailing the findings, which will allow researchers to receive, process, and review study data more efficiently and effectively.

"We are excited to work with Microsoft on another important initiative that extends our current work in support of standards-based process automation," said Sam Hume, CDISC VP, Data Science. "We look forward to building a community around CORE that will collaborate to create new innovative features and solutions."

"Microsoft is pleased to expand our work with CDISC to build the next generation CDISC Open Source Rules Engine to support Pharma Industry's digital transformation goals and ultimately accelerate time to market for life saving therapies." - Patty Obermaier, VP of Health and Life Sciences, Microsoft US.

To support and grow a community of open-source software developers, CDISC has initiated the CDISC Open Source Alliance (COSA). Several CDISC member organizations as well as individual developers have already committed to participate in COSA. Microsoft will provide ongoing guidance. Once released, CORE will become a COSA project supported by a global team of open-source developers and CDISC. A key component of COSA is community development.

CDISC collaborated with Microsoft on the Azure-based CDISC Library and CDISC 360, two projects that support standards-based process automation throughout the clinical research data lifecycle.

About CDISC

CDISC creates clarity in clinical research by convening a global community to develop and advance data standards of the highest quality. Required by the United States Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), recommended by the China National Medical Products Administration (NMPA) and adopted by the world's leading research organizations, CDISC standards enable the accessibility, interoperability, and reusability of data. With the help of CDISC standards, the entire research community can maximize the value of data for more efficient and meaningful research that has invaluable impact on global health. CDISC is a 501(c)(3) global nonprofit charitable organization with administrative offices in Austin, Texas, with hundreds of employees, volunteers, and member organizations around the world.

Most Popular Now

Open Call HORIZON-JU-IHI-2022-03-05: Dig…

Mental health disorders represent an area of severe unmet public health need. This has been further negatively impacted by the COVID-19 pandemic, with a substantial increase in the number and...

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Brain Area Necessary for Fluid Intellige…

A team led by UCL and UCLH researchers have mapped the parts of the brain that support our ability to solve problems without prior experience - otherwise known as fluid...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...